Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 4/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465945 | 0.91 | CTSS (0.33) | CYP3A4CTSSCTSLCTSKPTPN1 | |
| SCHEMBL7049753 | 0.79 | BCHE (0.41) | S1PR1CTSSCTSK | |
| SCHEMBL6464521 | 0.77 | CTSS (0.38) | CYP3A4CTSSCTSLCTSKPTPN1 | |
| SCHEMBL7049143 | 0.77 | HTT (0.34) | CYP3A4CTSS | |
| SCHEMBL6464414 | 0.75 | FAAH (0.38) | CYP3A4CTSS | |
| SCHEMBL6465509 | 0.74 | LMNA (0.46) | CYP3A4CTSSCTSL | |
| SCHEMBL7049338 | 0.74 | CTSS (0.38) | CTSSCTSLCTSK | |
| SCHEMBL6062750 | 0.73 | EPHX2 (0.38) | CYP3A4CTSS | |
| SCHEMBL6468432 | 0.73 | GART (0.34) | CYP3A4CTSS | |
| SCHEMBL7044860 | 0.73 | LMNA (0.44) | CYP3A4CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | SCN9A 2740/4885CYP3A4 1183/4885SCN10A 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.